Want to see HK:0911 full AI Analyst Report?
0911 Stock Chart & Stats
HK$0.28
-HK$0.03(-8.77%)
At close: 4:00 PM EST
HK$0.28
-HK$0.03(-8.77%)
Day’s Range― - ―
52-Week RangeHK$0.21 - HK$1.40
Previous CloseN/A
Volume500.00
Average Volume (3M)199.38K
Market Cap
HK$103.36M
Enterprise ValueHK$57.65M
Total Cash (Recent Filing)HK$61.38M
Total Debt (Recent Filing)HK$424.00K
Price to Earnings (P/E)29.0
Beta-0.21
Next Earnings
Aug 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding169,445,000
10 Day Avg. Volume241,207
30 Day Avg. Volume199,376
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.12
Price to Sales (P/S)0.07
P/FCF Ratio1.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low leverage and a large equity base provide durable financial flexibility and downside protection. This conservatism reduces refinancing and default risk, preserves capacity for opportunistic M&A or R&D spending, and helps the company withstand industry cyclicality over the medium term.
Improved Cash GenerationMaterial improvement in operating and free cash flow signals a structural uplift in cash conversion relative to prior years. Strong FCF provides internal funding for working capital, reinvestment, and resilience to shocks, lowering dependency on external capital and supporting sustainable operations over the next several quarters.
Return To Profitability & Revenue ReboundA robust revenue rebound and restored profitability indicate regained commercial traction and potential scale benefits. If revenue stability persists, this can support margin recovery, fund strategic initiatives, and form a foundation for multi-quarter earnings improvement rather than a short-lived uptick.
Bears Say
Very Low MarginsExtremely thin gross and net margins limit the company's ability to convert sales into durable profits. Low margin structure leaves earnings highly sensitive to modest cost increases or pricing pressure, constraining reinvestment capacity and making sustained profitability contingent on structural margin improvements.
Historical Cash-flow VolatilityWhile 2025 cash flow improved markedly, the company's history of multi-year operating cash burn demonstrates elevated operational risk. This volatility suggests that a reversal in sales or reimbursement could quickly erode cash generation and force reliance on external financing, limiting strategic optionality.
Low Returns On EquityModest ROE indicates limited efficiency in converting equity into earnings. A large equity base with low return reduces shareholder value creation potential over time and raises the bar for management to improve operational leverage or restructure capital to deliver stronger, persistent returns.
Qianhai Health Holdings Ltd. News
0911 FAQ
What was Qianhai Health Holdings Ltd.’s price range in the past 12 months?
Qianhai Health Holdings Ltd. lowest stock price was HK$0.20 and its highest was HK$1.40 in the past 12 months.
What is Qianhai Health Holdings Ltd.’s market cap?
Qianhai Health Holdings Ltd.’s market cap is HK$103.36M.
When is Qianhai Health Holdings Ltd.’s upcoming earnings report date?
Qianhai Health Holdings Ltd.’s upcoming earnings report date is Aug 25, 2026 which is in 22 days.
How were Qianhai Health Holdings Ltd.’s earnings last quarter?
Qianhai Health Holdings Ltd. released its earnings results on Mar 18, 2026. The company reported HK$0.007 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.007.
Is Qianhai Health Holdings Ltd. overvalued?
According to Wall Street analysts Qianhai Health Holdings Ltd.’s price is currently Overvalued.
Does Qianhai Health Holdings Ltd. pay dividends?
Qianhai Health Holdings Ltd. pays a Notavailable dividend of HK$0.1 which represents an annual dividend yield of N/A. See more information on Qianhai Health Holdings Ltd. dividends here
What is Qianhai Health Holdings Ltd.’s EPS estimate?
Qianhai Health Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Qianhai Health Holdings Ltd. have?
Qianhai Health Holdings Ltd. has 169,445,000 shares outstanding.
What happened to Qianhai Health Holdings Ltd.’s price movement after its last earnings report?
Qianhai Health Holdings Ltd. reported an EPS of HK$0.007 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Qianhai Health Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:0911
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Qianhai Health Holdings Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.26%
Trailing 12-Months
Company Description
Qianhai Health Holdings Ltd.
Qianhai Health Holdings Limited (0911.HK) functions as an investment holding company primarily focused on the distribution of health products and electronic components within Hong Kong. Its operations are structured into two main divisions: Health-Care Products and Electronic Component Products. The Health-Care Products segment supplies a range of items, including Chinese herbal medicines, various skincare and wellness products, and American ginseng, catering to both wholesale and retail clients. Concurrently, the Electronic Component Products division deals in items such as central processing units (CPUs) and semiconductors. Beyond these primary sales, the company also engages in the trading of both its health-care and electronic component offerings, alongside a money lending business. Established in 1989, the company underwent a name change in September 2016 from its previous identity, Hang Fat Ginseng Holdings Company Limited. It is headquartered in Sheung Wan, Hong Kong, and operates as a subsidiary of Explorer Rosy Limited.
Technical Analysis
Extrawell Pharmaceutical Holdings Limited
―
Tianda Pharmaceuticals Ltd.
―
Wai Yuen Tong Medicine Holdings Limited
―
PuraPharm Corp. Ltd.
―
Jacobson Pharma Corporation Limited
―